Risks of B12 Deficiency in Pregnancy Vitamin B12 levels tend to drop during pregnancy, which may increase the risk of a B12 deficiency
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
The 50mg vial is designed for long-term preclinical models, larger batch testing, or facilities running multiple concurrent metabolic studies that require a reliable, matched reference compound
Sergey Terushkin, MD, FACS Many patients compare themselves to dramatic before-and-after photos online
Do GLP-1 Medications Harm the Pancreas Over Time
However, the existing research provides intriguing signals that warrant further investigation
